Reconstructing individual patient data from Kaplan-Meier curves is a new approach for studying the effect of treatments on survival endpoints. The present review describes the application of this new method in comparing immune check-point inhibitors as first-line in advanced melanoma.

Microvessel density is a predictor of biochemical recurrence among prostate cancer patients.Moreover,in earlier T stage PCa is, a stronger microvessel density is associated with biochemical recurrence.

Using patient data from the SEER database to assess risk factors for cardiovascular death in Primary gallbladder carcinoma patients, the article adopts a competing risk model approach that can provide a clearer understanding of the link between Primary gallbladder carcinoma and cardiovascular disease. It can better help clinicians make relevant clinical decisions.

Extremely low-frequency pulsed electromagnetic field (ELF-PEMF), a specific magnetic field, is regarded as a potential adjuvant therapy for gliomas. This review summarizes significant underlying mechanisms and prospects of EMF-PEMF on gliomas.

Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of both oncology and non-oncology trials. In this paper we further elaborate on the challenges for patient participation in oncology trials from physician, patient, healthcare system, and some trial-related perspectives and present strategies such as use of digital healthcare technologies, real-world data and real-world evidence, decentralized clinical trials, pragmatic trial designs, and supportive services to increase patient participation.

There is a significant increased risk of some cutaneous AEs in patients using PI3K inhibitors. Further research are required to investigate the risk factors and pathogenesis.

We compared four different methods (portal vein infusion chemotherapy, hepatic arterial infusion chemotherapy, systematic chemotherapy, and surgery alone) for preventing liver metastasis in patients with colorectal cancer undergoing curative surgery by means of a network meta-analysis and concluded that hepatic arterial infusion chemotherapy might be a satisfactory method.

The frequency of CNVs and alternations of the reported genes.

In this systematic review, we appraise the adequacy of health-related quality of life reporting in phase-III randomized controlled trials of stage III-IV cutaneous melanoma, and the clinical issues of immunotherapy and small-molecular targeted therapy on health-related quality of life. The potential effect of reporting might yield new insights into clinical decision making.

Inclusion criteria.

More than half of elderly patients who undergo curative resection for colorectal cancer die of other diseases. The CONUT score was the most useful predictor of non-CRC-related death in these patients.

(1) In 92 patients, the multidrug chemotherapy group showed better efficacy than the single-agent chemotherapy group and the PD-1 inhibitors group, with an ORR of 35.3%, 6.0%, and 12.5%, respectively (p = 0.006). (2) In second-line therapy, the median PFS was 5.0 months for multidrug chemotherapy, 3.0 months for monotherapy and 4.0 months for PD-1 inhibitors (p = 0.008). (3) The multidrug chemotherapy group had an advantage over the other groups in OS (p = 0.045), with median OS of 30.4 months.

For patients with hepatocellular carcinoma (HCC) within the Milan Criteria (MC), three curative-intent treatment options are liver transplantation (LT), resection (LR) and ablation (LA). This online prognostic calculator was developed based on the preoperative clinical factors that were independently associated with outcomes to evaluate and compare recurrence-free survival (RFS), recurrence within the Milan criteria (RWM), and HCC-specific survival (HSS) at different time intervals for all three treatment options. Patients who recurred within the MC are potentially eligible for salvage transplantation.

Favorable relapse-free survival was observed after pembrolizumab discontinuation in patients with urothelial carcinoma, especially in those with complete responses, higher hemoglobin levels, and better ECOG-PS at the time of discontinuation. Re-administration upon progression was effective in 90.9% of the patients, and no difference in overall survival was observed between the patients who continued or discontinued treatment after complete or partial responses.

Pyrotinib, a novel irreversible epidermal growth factor receptor 2 (EGFR)/HER2 dual tyrosine kinase inhibitor, has shown promising antitumor efficacy and tolerable toxicity in HER2-positive metastatic breast cancer (MBC) in several clinical trials. Whereas, the clinical trials do not usually well reflect the condition of patients in real clinical settings. Our study showed that the pyrotinib-based regimen can effectively treat HER2-positive MBC in real world, including patients, who progressed after lapatinib treatment and with brain metastasis, and drug-related toxicity are acceptable.

Genetic testing is recommended for all pancreatic ductal adenocarcinoma (PDAC) patients. Limited information exists regarding the utility of integrated genetics in the multidisciplinary pancreatic cancer clinic setting. We found that integrating genetics into the multidisciplinary setting significantly improved genetic testing compliance by reducing logistical barriers for PDAC patients, and clarified cancer risks for their relatives while conserving clinical resources.

Cardiac metastasis occurs in 2% of patients with metastatic melanoma, can affect all cardiac structures, and is associated with high mortality. Cardiovascular complications may occur after the diagnosis of cardiac metastasis of melanoma, however with limited impact on mortality, which is predominantly due to progression of malignancy.

Patients treated with surgery combined with postoperative ¹²⁵I seed radiotherapy have a higher overall survival rate, and those with perineural invasion are more suitable for radioactive seed implantation therapy.

Real-word data on use of the flat-dose nivolumab 480 mg Q4W regimen for the adjuvant treatment of melanoma are limited. Findings from the current study suggest that the real-world safety and tolerability profiles of nivolumab 240 mg Q2W and 480 mg Q4W are similar and that both are comparable to weight-based dosing (3 mg/kg Q2W), adding to existing data supporting their approval and use as adjuvant treatments for melanoma.

FLOX/OX treatment was associated with improved overall survival (OS) and improved cancer specific survival in stage III patients compared with 5-FU/LV and the survival benefit of FLOX/OX was sustained in stage III patients aged 70 years. Capecitabine had the lowest emergency room visit/hospitalization among the three regimens with 19.2% in stage II and 28.9% in stage III patients.

The incidence rates of delirium were 17.1% for men and 15.3% for women with cancer. Compared to gastric cancer, the risk of delirium was significantly higher for pancreatic cancer, leukemia, and oropharyngeal cancer.

The response of neoadjuvant TPF chemotherapy in patients with oral cavity cancer was related to the disease stage, especially the nodal stage. Patients with bulky nodes or lymph node with obvious necrosis may have low response. Patients with complete or partial response developed less progression events and better survival.

Kaplan–Meier curve of performance-free survival of cutaneous and melanoma of unknown primary patients stratified by prognostic criteria. LDH, lactate dehydrogenase; mPFS, median performance survival; ULN, upper limit of normal.

NCT could had its efficiency in patients with dMMR colon cancer regarding to tumor regression grade and the rate of multiorgan resection. Large-scaled prospective researches are needed to verify our results and further explore more individual systemetic treatment for patients with colon cancer.

To evaluate whether measurement of urine laminin-γ2 monomer (Ln-γ2m) offers a useful biomarker for patients with non-muscle invasive bladder cancer (NMIBC). The measurement of urine Ln-γ2m offers a potentially useful biomarker for NMIBC, particularly in cases of low-grade cancer.

Non-invasive methods to predict the response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer could help clinicians develop individualized treatment strategies. In this work, we retrospectively enrolled 215 patients with locally advanced rectal cancer who received neoadjuvant chemoradiation therapy, and we analyzed their pretreatment radiotherapy planning CT images for both radiomic and traditional radiological features. A machine learning model built with the selected radiomics and clinicopathological features. achieved satisfying performance for predicting non-response to neoadjuvant chemoradiation therapy with an area under the curve (AUC) value of 0.92 for the training cohort and 0.89 for the validation cohort. The machine learning model outperformed a traditional logistic regression model. These findings support the use of radiomics for clinical decision-making in locally advanced rectal cancer.

This retrospective case–control study enrolled patients (n = 378) with multiple primary melanoma (MPM) and single primary melanoma (SPM) at a 1:2 ratio and evaluated the association between MPM and other cancers using logistic regression models. Compared with patients with SPM, patients with MPM were more likely to have squamous cell carcinoma (OR 1.95, 95% CI 1.001–3.79, p = 0.047), basal cell carcinoma (OR 1.66, 95% CI 0.99–2.74, p = 0.051), and prostate cancer (OR 2.72, 95% CI 1.07–7.01, p = 0.034).

Tumor response remains an important factor for selecting patients with limited-stage small-cell lung cancer for prophylactic cranial irradiation (PCI) in the magnetic resonance imaging era. PCI should still be considered for patients with complete response after initial thoracic radiotherapy.

Our newly defined classification has a better discrimination ability to predict survival outcome and recurrence score of Luminal B (HER2 negative) breast cancer, which may help in clinical decision-making for individual treatment.

Understanding the risk of pancreatic cancer following an acute pancreatitis diagnosis is a critical component to early intervention for pancreatic cancer in this high-risk population as multiple data sets have demonstrated that early detection can lead to an increased percentage of patients diagnosed with stage I disease, and hence an improved chance for cure.

Bilateral involvement was associated with a poor prognosis of OAML and call for extended surveillance of disease progression for patients with bilateral involvement. Among patients with residual lesions after surgical treatment, further consolidation treatment could lead to improved survival, compared with watchful waiting. Systemic treatment might be considered as a treatment candidate, given the noted rare adverse event.

Preoperative multi-modal magnetic resonance imaging radiomic study could distinguish IDH-mutant TERT promoter-mutant gliomas from other gliomas. Contrast-enhanced T1, FLAIR, and ADC maps played an important role in detecting IDH-mutant TERT promoter-mutant gliomas. MR imaging of IDHmut pTERTmut gliomas showed homogenous low-complexity texture in three modalities.

The coN staging combining TDs and LNMs results in more powerful prognositic prediction than the conventional N staging in stage III colon cancer.

This study shows that CEUS features of malignant and benign renal tumors change along with the tumor size. The use of CEUS features in the diagnosis of benign and malignant tumors requires consideration of tumor size.

To our knowledge, this is the first study that applied PI-RADS 3 subgroup into nomogram. Overall, the nomogram is a promising tool for predicting prostate cancer and clinically significant prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions due to the good calibration and net benefit. Our model may assist urologists in biopsy decision making for the “double gray zone” patients.

Lenvatinib showed consistent efficacy and toxicity profiles in patients with post-LT HCC recurrence that were comparable to those reported from previous studies among non-LT HCC patients. The baseline ALBI grade correlated with better OS in post-LT lenvatinib-treated patients.

In sarcopenic cancer patients, the influence of altered body composition on clinical outcome of anticancer drug therapy is still not completely understood. Results from population pharmacokinetic modeling and logistic regression suggest that skeletal muscle index (SMI) measures may be associated with clearance of fluorouracil (5FU) and the occurrence of fatigue and polyneuropathy, respectively. These relationships deserve further investigation.

In this overall and individual level meta-analysis, patients with hepatocellular carcinoma treated with transarterial chemoembolization and transarterial radioembolization (TARE) showed similar survival. Patients treated with TARE however, had a longer time to tumor progression.

Based on a large data set of prostate cancer patients, we developed and valdated prognostic nomograms and demonstrated their favourable ability in predicting 1-, 3-, 5-, and 10-year overall and cancer-specific survival for prostate cancer patients. We further proposed the prognostic scoring system for the first time to more intuitively present the influence of clinical pathological factors on overall and cancer-specific survival of prostate cancer. The proposed survival model of prostate cancer can help clinicians select individualized and effective treatment.

This article investigated the clinical characteristics and survival outcomes of a rare lymphoma subtype, primary gastrointestinal natural killer (NK)/T-cell lymphoma. To date, this is the largest series of cases reported at a single medical center. The median OS was 4.0 months and a 2-year OS rate of 30.7%. Moreover, we observed that perforation, serum LDH ≥ULN and EOCG PS score ≥2 were markedly associated with worse OS.

Survivors of non-Hodgkin lymphoma (NHL) have increased secondary malignancy (SM) risk. Treatment with radiotherapy did not increase overall SM risk, while chemotherapy was associated with a higher overall risk. However, certain sub-sites were associated with higher risk of SM, and they varied by treatment, age group, race and time since treatment." cd_value_code="text

This study developed a Bayesian network (BN) survival prognostic model for PMP which has a resonable level of predictive performation. The BN model can help oncologists to make clinical decisions.

Our data suggest that Atezo+Bev treatment has a good anti-tumor effect on mALBI 1+2a and a reasonable transition rate to the subsequent molecular-targeted agents treatment.

In this real-life study, we investigate the efficacy and safety of second-line epirubicin-paclitaxel regimen in 29 extensive-stage small-cell lung cancer (ES-SCLC) patients. Our results highlight promising survival outcomes, significative systemic activity and favorable toxicity profile. This association seemed to be effective and could represent another valuable therapeutic option in a pre-treated ES-SCLC population.

Atezolizumab plus pemetrexed and cisplatin (APP) versus pemetrexed plus cisplatin (PP) was studied in Chinese patients with non-squamous advanced non-small cell lung cancer in IMpower132. Progression-free survival benefit was seen with APP versus PP; there was a trend toward overall survival benefit favoring APP versus PP, though interim overall survival data were immature at this analysis. No new safety signals were seen with APP in Chinese patients.

This SEER-based study assessed the survival benefits of primary tumor surgery (PTS) in patients with brain metastases (BMs). PTS appeared to significantly prolong cause-specific survival (CSS) time for patients with BMs secondary to non-small cell lung cancer, breast cancer, renal cancer, and colorectal cancer, rather than BMs from small cell lung cancer, melanoma, and liver cancer.

This study demonstrated that the quality of integrated female oncofertility care measured with a set of systematically developed quality indicators is far from optimal and needs improvement.

BMI is independently associated with clinical outcomes in patients with R/M HNSCC. Compared to normal patients, underweight patients tend to mean higher risk of death. In survival analysis, overweight and obese patients have better OS and PFS than normal weight patients, and underweight patients had poorer prognosis.

CT quantitatively analyzed the changes in skeletal muscle and visceral fat in patients with pancreatic cancer before and after surgery, to dynamically and objectively reflect the impact of different surgical methods on the pre- and postoperative nutritional status of patients.

Fine-needle aspiration (FNA) has a high positive predictive value (PPV) for detecting malignancy in the soft tissue lesions. For patients with resectable lesions and malignant FNA, the core needle biopsy (CNB) step can be omitted with multidisciplinary evaluation, and subsequent radical surgery can be performed.

The non-interventional study MabSCale assessed the effectiveness and safety of subcutaneous rituximab for the treatment of follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL). The results confirm the effectiveness and safety of subcutaneous rituximab in both the FL and the DLBCL group. Furthermore, patient and nurse satisfaction with subcutaneous administration was high.

This study proposed a novel TNM staging system for urachal carcinoma based a large number of patients in NCDB. It provides a more balanced sample distribution and a more accurate stage-survival correlation than the traditional Sheldon, Mayo, and Ontario staging systems. It is clinically applicable and enables better risk stratification, prognosis, and therapeutic decision-making.

In the global, open-label, phase 3 EV-301 trial, enfortumab vedotin (EV) demonstrated clinically significant overall survival (OS) benefit compared with standard chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. This subgroup analysis of EV-301 Japanese patients confirmed that EV demonstrated an OS benefit and no new safety signals identified in the Japanese subpopulation, consistent with the efficacy and safety/tolerability in the EV-301 overall study population.

The nomogram predicting distant-metastasis-free survival(DMFS) based on the clinicopathological factors and immune-inflammation index for the major salivary gland carcinoma.

Kaplan–Meier survival curves and log-rank tests were used to evaluate the effect of different reconstruction methods (implant, autologous, implant and autologous combined reconstruction) on the overall survival (OS) of triple negative breast cancer patients. All three reconstruction methods had higher OS and lower risk than mastectomy alone (p < 0.0001). Among the three reconstruction methods, autologous reconstruction has the lowest survival rate and the highest risk.

We performed a retrospective propensity score-matched cohort study to assess the therapeutic responses and survival outcomes of AML patients with PHF6 mutation compared with those without PHF6 mutation after balancing age, sex and risk categories. Our data revealed that PHF6 mutation was associated with a lower chemotherapy response and shorter survival, suggesting that PHF6 mutation is a predictor of poor prognosis in AML.

Comparison of outcomes by tamoxifen exposure among 151 women with breast cancer history.

HGS, ALI, SII, NLR, and PLR were independent risk factors for overall survival of lung cancer patients. Co-occurrence of low HGS and systemic inflammation significantly elevated the risk of death. The predictive ability of handgrip weakness combined with low ALI for OS was better than the other three combinations.

In this study, serum parameters of liver function tests in patient with gastric cancer liver metastasis (GCLM) were analyzed by lasso regression; a liver chemistry score (LCS) was generated as 0.03343515 × ln (AST, U/L) + 0.02687997 × ln (ALP, U/L). Patients in low (LCS < 0.232) or high (LCS = 0.232) score group experienced different survival times. The score was also demonstrated as an independent prognostic factor for GCLM patients and incorporated into predictive nomogram model.

In response to COVID-19 and disparities in access determined by socioeconomic factors, we assessed the impact of a personalized digital support structure, the Telehealth Task Force (TTF), to reduce disparities in TH. Implementation of the TTF helped close the digital divide; increasing TH access for vulnerable patients. Attention to digital readiness can mitigate disparities in access to care.

Surgical resection can be considered for selected patients with colorectal PM because a significant number of them could seize the cure changes during their treatment continuum.

Real world study depicting prevalence of KRAS mutated NSCLC (30.6%) in India with G12C seen in 34% cases. Co-mutations were higher in non G12C subgroup (p&#60;0.05), and the PFS with chemotherapy was longer in G12C subgroup (6.4 months vs. 3.8 months).

Number of reclassified unique variants of uncertain significance (VUS) by gene as a function of the total number of VUS. The number of unique VUS is shown on the right axis and that number of reclassifications are on the left axis.

This real-world study identified certain baseline patient and tumor characteristics, medical and medication histories, changes of weight and food intake, diet, and self-care ability which were independently associated with in-hospital outcomes among 20,650 older patients (≥65 years) with cancer admitted to a top-ranked hospital in China during 2016-2020, and which should be paid special attention to. Our study can help to identify patients at higher risks of inferior in-hospital outcomes.

We analyzed pre-NAT tumor biopsies from TNBC, HR+, and HER2+ breast cancer patients who received NAT and compared the different immune makers (PD-1, PD-L1, CD3, and CD8) of tumor-infiltrating lymphocytes (TILs). We found PD-L1+ cells were significantly higher in TNBC patients than others, and PD-L1+ cells were higher in pathologic complete response (pCR) than in no-pCR TNBC patients. Our results demonstrated that TNBC patients had significantly different TME, suggesting a potential role for immunotherapy in these patients.

We performed post-hoc analyses of the ONO-7643-04 study to investigate the efficacy and safety of anamorelin in subgroups of Japanese patients with non-small cell lung cancer. This study revealed consistent improvements in lean body mass, body weight, and appetite score using QOL-ACD item 8 across most subgroups of anamorelin-treated patients versus placebo. This study also demonstrated the tolerability of anamorelin regardless of age and performance status, with a low incidence of serious adverse drug reactions in each subgroup.

In this paper, we assessed the impact of prior cancer history on survival of patients with hypopharyngeal cancer. The results showed that the previous cancer diagnoses did not significantly impact the hypopharyngeal carcinoma patients' overall survival, which means maybe more hypopharyngeal cancer patients with prior cancer should be considered for clinical trials.

This study indicats the similar efficacy, PFS, and OS in patients treated by VRd and IRd. Moreover, IRd shows better safety than VRd, and it may be more convenient for patients with poor basic condition. This study provides an insight for physicians to use IRd as first-line treatment in MM.

Differentially enriched bacterial species in young onset colorectal cancer patients.

This study is one of the largest studies to examined the risk of colon cancers in patients with AMI. The results showed that AMI was associated with a significantly higher risk of colon cancer in the female patients, but not in the male patients. Cardiologists who treat patients with acute myocardial infarction should be aware of colon cancer risk, especially in women.

Antiangiogenic therapy (Apatinib) plus chemotherapy had better efficacy compared with standard second-line chemotherapies for advanced SCLC patients. No more intolerable toxicities were observed for this new regimen, which should provide a highlight view on the current status of second-line therapy in SCLC.

Asciminib, a first-in-class, allosteric inhibitor of BCR-ABL1 that acts by STAMP (Specifically Targeting the ABL Myristoyl Pocket), is a novel therapeutic option for patients with chronic myeloid leukemia (CML). In the global, phase 3, open-label ASCEMBL study in patients with CML in chronic phase (CML-CP) pretreated with = 2 tyrosine kinase inhibitors (TKIs), asciminib (40 mg twice-daily) demonstrated statistically significant superiority over the ATP-competitive TKI bosutinib (500 mg once daily) for the primary endpoint of major molecular response (MMR; BCR-ABL1 transcript levels on the international scale [BCR-ABL1IS] = 0.1%) at week 24. Here, we present a descriptive subgroup analysis results of Japanese patients enrolled in the ASCEMBL study.

We investigated the risk factors associated with decline in understanding speech as measured by speech recognition threshold among testicular cancer survivors. Associated factors were higher BMI, lower physical activity and smoking, and peripheral motor neuropathy alongside genetic variants with suggestive associations including those related to three genes involved in neuronal development.

Patients with multiple myeloma should receive herpes zoster prophylaxis drugs while receiving active cancer-related treatment. Those who receive stem cell transplants, either autologous or allogeneic, are also at high risk of getting herpes zoster infection, even under prophylaxis.

The current study investigated the outcomes in anaplastic thyroid carcinoma (ATC) patients treated by paclitaxel as neoadjuvant setting. Prognostic index ≥2, response to paclitaxel, resection, and radiotherapy were independent prognostic factors in ATC patients treated with paclitaxel as neoadjuvant setting.

The advanced clinical stage of the disease (non-IE according to the Ann Arbor) concerns two thirds of the overall population of patients with ocular adnexal lymphoma and one third of MALT lymphoma patients. Due to the high prevalence of advanced stages of ocular adnexal lymphoma, treatment with combined therapies is warranted. Combined treatment tends to improve PFS compared to chemotherapy alone in the overall population of patients with ocular adnexal lymphoma.

Hepatocellular carcinoma treatment in limited resource countries was limit due to cost. Real-world evidence reflects clinical effectiveness in general practice. Even though FOLFOX had significant shorter survival than Sorafenib, but FOLFOX still extended median overall survival by 8.2 months.

The management of elderly patients with MM remains challenging due to the heterogeneity of disease conditions, especially immune deficiency. In order to provide more evidence-based practice for the elderly MM, the study established and assessed a stratified therapeutic model with studies on Regulatory B cells for Chinese Elderly Multiple Myeloma in 2021 (CEMM2021).

The positive role of tertiary lymphoid structure in tumor has received much attention, but peritumoral tertiary lymphoid structure in Hepatocellular Carcinoma has a different picture, which may be associated with neutrophil infiltration.

It is the first study that develope an effective survival prediction model for patients with ES. Using this nomogram can assist in clinical decision-making as it has satisfactory accuracy. Even so, additional external validation is needed.

This study identified ten factors including nine gene mutations and smoking history as predictors for the organ tropism metastasis of NSCLC through analyses of NGS data and other clinical factors. Then three models were established to predict lung metastasis, brain metastasis, and pleura dissemination of NSCLC using these factors.

Front-line treatment for elderly MM patients.

Waterfall plot showing changes from baseline at Week 12 in tumor volume (on left) and tumor diameter (on right). Green bars represent responses in the Varlitinib + Capecitabine arm; red bars represent responses in the Lapatinib + Capecitabine arm.

In a nationwide cohort of 74,373 primary breast cancer (PBC) patients, patients with lobular and especially those with lobular mixed histology had higher contralateral breast cancer (CBC) risks as compared to patients with ductal histology. Systemic treatment was associated with decreased CBC risk in all patients. The results of this study contribute to personalized risk assessment, with potential impact on treatment and follow-up decisions for PBC.

Watchful waiting is expected to produce no inferior time to next treatment (A) and progression free survival (B) compared to radiation or rituximab monotherapy in patients with primary ocular adnexal mucosa-associated lymphoid tissue lymphoma, especially those without eye-related symptom.

Frequently, transplant-ineligible patients are those who are frail and/or elderly, highlighting an unmet medical need for tolerable therapies; one approach to sustaining response balanced with tolerability is the use of maintenance or dose-attenuated therapies. Among newly diagnosed multiple myeloma patients who did not receive stem cell transplant, dose-attenuated first-line therapy was associated with longer duration of therapy vs first-line therapy without dose-attenuation. Each additional month of first-line therapy was associated with a reduced adjusted likelihood of disease progression and death at 2 years.

We aimed to evaluate the activity of single-agent gemcitabine in the largest series of 42 patients with advanced angiosarcoma. The best tumor response was partial response (PR) in 16 patients (38%), or stable disease (10 patients, 24%), median PFS was 5.4 months, and median OS was 9.9 months. Single-agent gemcitabine has clinically meaningful activity in advanced, heavily pre-treated angiosarcoma.

Coding sequences of BRCA1, BRCA2, ATM, TP53, and PALB2 were analyzed in 68 consequtive Chechen patients with high-grade serous ovarian cancer and 79 patients with breast cancer. The recurrent BRCA1 pathogenic variant was identified.

In this study, we retrospectively evaluated the efficacy of an androgen receptor-axis-targeted therapies (ARAT) switch from apalutamide or enzalutamide to darolutamide for non-metastatic castration-resistant prostate cancer (nmCRPC). More than half of the patients had a PSA response of more than 50% decline after starting darolutamide. Darolutamide could be the option of sequential therapy in patients with nmCRPC resistant to other ARAT.

We analyzed BCR::ABL1 expression at stop and in the first month after discontinuation in 168 CML patients stopping imatinib or 2G-TKIs, dividing patients who maintained response (1, n = 123) and those who lost MMR (group 2, n = 45). Mean BCR::ABL1 RNA levels at 1 and 2 months after discontinuation was higher in group 2 than in group 1, with a similar trend for imatinib and 2G-TKIs. A BCR::ABL1 value <0.0051% at 1 month after discontinuation was the stronger predictor of treatment-free remission (92.2% specificity).

MiR-204-5p regulates tumorigenesis and progression via various target genes in human cancers.

Our review analyses and discusses the recent basic research and clinical application of hyperthermia combined with immune checkpoint inhibitors for malignant tumors treatment. And the development tendency of this therapy is set forth constructively, which aims to provide a helpful guide to follow-up practice.

Endomucin (EMCN) was overexpressed in tumor tissues compared to normal para-carcinoma tissues. overexpression of EMCN induced colorectal cancer proliferation and metastasis both in vitro and in vivo experiments. identified EMCN-binding proteins were significantly enriched in carcinogenesis related functions and pathways.